Press Release Details

On September 15, 2022, Caladrius Biosciences, Inc. (CLBS) and Cend Therapeutics, Inc. (private) announced the closing of a merger between the two companies, The merged company now operates as Lisata Therapeutics, Inc. (LSTA). Their development efforts focus primarily on advancing the CendR Platform™ product candidates in a range of oncology indications, in addition to existing CD34+ development programs begun under CLBS. WBB has covered LSTA’s precursor companies since 2010.